Katerina M Antoniou

List of Publications by Year
in descending order

66 papers	4,520 citations	172207 29 h-index	123241 61 g-index
66 all docs	66 docs citations	66 times ranked	5154 citing authors

#	Article	IF	Citations
1	Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries. ERJ Open Research, 2022, 8, 00597-2021.	1.1	21
2	European Respiratory Society statement on long COVID follow-up. European Respiratory Journal, 2022, 60, 2102174.	3.1	81
3	Patients with idiopathic pulmonary fibrosis with and without obstructive sleep apnea: differences in clinical characteristics, clinical outcomes, and the effect of PAP treatment. Journal of Clinical Sleep Medicine, 2021, 17, 533-544.	1.4	23
4	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. European Respiratory Journal, 2021, 57, 2100048.	3.1	152
5	Precision medicine in idiopathic pulmonary fibrosis therapy: From translational research to patient-centered care. Current Opinion in Pharmacology, 2021, 57, 71-80.	1.7	7
6	Enhanced IL-1Î² Release Following NLRP3 and AIM2 Inflammasome Stimulation Is Linked to mtROS in Airway Macrophages in Pulmonary Fibrosis. Frontiers in Immunology, 2021, 12, 661811.	2.2	43
7	PAP therapy in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea: multum non multa. Journal of Clinical Sleep Medicine, 2021, 17, 1327-1328.	1.4	0
8	Realâ€'life Cretan asthma registry focused on severe asthma: On behalf of â€˜The Cretan registry of the use of Biologics in Severe Asthmaâ€™. Experimental and Therapeutic Medicine, 2021, 22, 1239.	0.8	1
9	Early COVID-19 lockdown in Greece and idiopathic pulmonary fibrosis: a beneficial â€œimpactâ€•beyond any expectation. European Respiratory Journal, 2021, 57, 2003111.	3.1	11
10	Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target. Frontiers in Immunology, 2021, 12, 687397.	2.2	22
11	Circulating miRNAs as Potential Biomarkers in Prostate Cancer Patients Undergoing Radiotherapy. Cancer Management and Research, 2021, Volume 13, 8257-8271.	0.9	3
12	Collagen 1a1 Expression by Airway Macrophages Increases In Fibrotic ILDs and Is Associated With FVC Decline and Increased Mortality. Frontiers in Immunology, 2021, 12, 645548.	2.2	17
13	A role of antifibrotics in the treatment of Scleroderma-ILD?. Pulmonology, 2020, 26, 1-2.	1.0	5
14	Obstructive sleep apnea in pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2020, 26, 443-448.	1.2	14
15	Management of Patients with Interstitial Lung Disease in the Midst of the COVID-19 Pandemic. Respiration, 2020, 99, 625-627.	1.2	14
16	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153.	2.5	60
17	Human pentraxin 2 protein treatment for IPF. Lancet Respiratory Medicine,the, 2019, 7, 640-641.	5.2	6
18	Interstitial lung abnormalities: ignotum per ignotius. Lancet Respiratory Medicine,the, 2019, 7, 376-378.	5.2	7

#	Article	IF	Citations
19	Accumulation of damaged mitochondria in alveolar macrophages with reduced OXPHOS related gene expression in IPF. Respiratory Research, 2019, 20, 264.	1.4	33
20	Pirfenidone improves survival in IPF: results from a real-life study. BMC Pulmonary Medicine, 2018, 18, 177.	0.8	65
21	NLRP3/Caspase-1 inflammasome activation is decreased in alveolar macrophages in patients with lung cancer. PLoS ONE, 2018, 13, e0205242.	1.1	31
22	Paroxysmal cough and leftÂsacroiliac joint pain in a 50-year-old Caucasian man. Breathe, 2018, 14, e59-e67.	0.6	0
23	New respiratory symptoms and lung imaging findings in a woman with polymyositis. Breathe, 2018, 14, e34-e39.	0.6	0
24	Controversies in Fibrosis and Emphysema. Archivos De Bronconeumologia, 2017, 53, 231-232.	0.4	0
25	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international caseâ€“cohort study. European Respiratory Journal, 2017, 50, 1700936.	3.1	75
26	Controversies in Fibrosis and Emphysema. Archivos De Bronconeumologia, 2017, 53, 231-232.	0.4	1
27	Towards a global initiative for fibrosis treatment (GIFT). ERJ Open Research, 2017, 3, 00106-2017.	1.1	5
28	Effect of Emphysema Extent on Serial Lung Function in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1162-1171.	2.5	69
29	Mesenchymal stem cell treatment for IPFâ€”time for phase 2 trials?. Lancet Respiratory Medicine,the, 2017, 5, 472-473.	5.2	5
30	Toll-like receptors and autophagy in interstitial lung diseases. European Journal of Pharmacology, 2017, 808, 28-34.	1.7	11
31	Upregulation of citrullination pathway: From Autoimmune to Idiopathic Lung Fibrosis. Respiratory Research, 2017, 18, 218.	1.4	47
32	Aberrant expression of miR-21, miR-376c and miR-145 and their target host genes in Merkel cell polyomavirus-positive non-small cell lung cancer. Oncotarget, 2017, 8, 112371-112383.	0.8	17
33	Medical Therapy in Idiopathic Pulmonary Fibrosis. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 368-377.	0.8	20
34	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 265-275.	2.5	1,006
35	Smokingâ€related idiopathic interstitial pneumonia: A review. Respirology, 2016, 21, 57-64.	1.3	59
36	NLRP3 inflammasome expression in idiopathic pulmonary fibrosis and rheumatoid lung. European Respiratory Journal, 2016, 47, 910-918.	3.1	89

#	Article	IF	Citations
37	MiR-185/AKT and miR-29a/Collagen 1a pathways are activated in IPF BAL cells. Oncotarget, 2016, 7, 74569-74581.	0.8	22
38	Idiopathic pulmonary fibrosis and lung cancer. Current Opinion in Pulmonary Medicine, 2015, 21, 626-633.	1.2	67
39	Clinical highlights: messages from Munich. ERJ Open Research, 2015, 1, 00002-2015.	1.1	0
40	New Treatments for Idiopathic Pulmonary Fibrosis: â€˜Die Another Day' if Diagnosed Early?. Respiration, 2015, 90, 352-352.	1.2	9
41	Smoking and interstitial lung diseases. European Respiratory Review, 2015, 24, 428-435.	3.0	56
42	An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. European Respiratory Journal, 2015, 46, 976-987.	3.1	803
43	Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night. European Respiratory Review, 2015, 24, 327-339.	3.0	59
44	Early diagnosis of IPF: time for a primary-care case-finding initiative?. Lancet Respiratory Medicine,the, 2014, 2, e1.	5.2	15
45	Interstitial Lung Disease in Systemic Sclerosis. Seminars in Respiratory and Critical Care Medicine, 2014, 35, 213-221.	0.8	53
46	Combination therapy: the future of management for idiopathic pulmonary fibrosis?. Lancet Respiratory Medicine,the, 2014, 2, 933-942.	5.2	128
47	An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respiratory Medicine,the, 2014, 2, 123-130.	5.2	178
48	Interstitial lung disease. European Respiratory Review, 2014, 23, 40-54.	3.0	182
49	The Prognostic Value of the GAP Model In Chronic Interstitial Lung Disease. Chest, 2014, 145, 672-674.	0.4	10
50	Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future. European Respiratory Review, 2013, 22, 281-291.	3.0	52
51	The pathogenesis of pulmonary fibrosis: a moving target. European Respiratory Journal, 2013, 41, 1207-1218.	3.1	252
52	Acute Exacerbations of Idiopathic Pulmonary Fibrosis. Respiration, 2013, 86, 265-274.	1.2	43
53	Molecular pathological findings of Merkel cell polyomavirus in lung cancer: A possible etiopathogenetic link?. International Journal of Cancer, 2013, 133, 3016-3017.	2.3	4
54	Detection of Herpes Simplex Virus Type-1 in Patients with Fibrotic Lung Diseases. PLoS ONE, 2011, 6, e27800.	1.1	40

#	Article	IF	Citations
55	Expression analysis of Akt and MAPK signaling pathways in lung tissue of patients with idiopathic pulmonary fibrosis (IPF). Journal of Receptor and Signal Transduction Research, 2010, 30, 262-269.	1.3	36
56	Investigation of bone marrow mesenchymal stem cells (BM MSCs) involvement in idiopathic pulmonary fibrosis (IPF). Respiratory Medicine, 2010, 104, 1535-1542.	1.3	40
57	Expression Analysis of Angiogenic Growth Factors and Biological Axis CXCL12/CXCR4 Axis in Idiopathic Pulmonary Fibrosis. Connective Tissue Research, 2010, 51, 71-80.	1.1	34
58	Different Activity of the Biological Axis VEGF-Flt-1 (fms-Like Tyrosine Kinase 1) and CXC Chemokines between Pulmonary Sarcoidosis and Idiopathic Pulmonary Fibrosis: A Bronchoalveolar Lavage Study. Clinical and Developmental Immunology, 2009, 2009, 1-8.	3.3	19
59	Different angiogenic CXC chemokine levels in bronchoalveolar lavage fluid after interferon gamma-1b therapy in idiopathic pulmonary fibrosis patients. Pulmonary Pharmacology and Therapeutics, 2008, 21, 840-844.	1.1	15
60	Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 190-194.	2.5	161
61	Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2007, 20, 453-461.	1.1	67
62	Quality of life in patients with active sarcoidosis in Greece. European Journal of Internal Medicine, 2006, 17, 421-426.	1.0	22
63	Different Angiogenic Activity in Pulmonary Sarcoidosis and Idiopathic Pulmonary Fibrosis. Chest, 2006, 130, 982-988.	0.4	77
64	Upregulation of Th1 Cytokine Profile (IL-12, IL-18) in Bronchoalveolar Lavage Fluid in Patients with Pulmonary Sarcoidosis. Journal of Interferon and Cytokine Research, 2006, 26, 400-405.	0.5	34
65	Investigation of IL-18 and IL-12 in induced sputum of patients with IPF before and after treatment with interferon gamma-1b. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2005, 22, 204-9.	0.2	4
66	Th1 cytokine pattern (IL-12 and IL-18) in bronchoalveolar lavage fluid (BALF) before and after treatment with interferon gamma-1b (IFN-gamma-1b) or colchicine in patients with idiopathic pulmonary fibrosis (IPF/UIP). Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2004, 21, 105-10.	0.2	18